الفهرس 
Lymphatic systemOnly 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
Summary The Non Hodjkin Lymphoma (NHL) are a heterogeneous groups of lymphoproliferative malignancies with differing pattern of behaviour, prognosis and response to treatment. Combination chemotherapy remains the cornerstone of treatment for most newly diagnosed and relapsed/refractory lymphoma patients. Two new chemotherapeutic agents, vinorelbine and gemcitabine, have shown encouraging early results in the treatment of heavily pretreated relapsed or refractory lymphoma when used as single agents, with responses of between 20 and 47%. This study aimed to evaluate the role of vinorelbine and gemcitabine in treatment of relapsed or refractory NHL. This prospective study was conducted on 20 patients who had relapsed and /or refractory aggressive NHL and were treated at Clinical Oncology and Nuclear Medicine department, Tanta University Hospital and health insurance hospitals throughout period of September 2017 to December 2018 with a minimum follow up period of 6 months. All eligible patients were subjected to full clinical examination, laboratory and radiological study. Venorelbin , Gemcitabin, dexamethasone, filgrastim (VGF) was administrated , On days 1 and 8, patients received vinorelbine 25 mg/m2, Gemcitabine 1000 mg/m2 and Dexamethasone 16mg/m2i.v, On day 9, they received peg-filgrastim 6 mg subcutaneously, Patients will receive 4 cycles of (VGF), Assessment was performed after 4th cycle of treatment and according to response during follow up period patient received 2 more cycles with minimum